BTAI
BioXcel Therapeutics, Inc.
Price Chart
Latest Quote
$1.20
+0.01 (+0.84%)
Current Price
| Previous Close | $1.19 |
| Open | $1.20 |
| Day High | $1.23 |
| Day Low | $1.18 |
| Volume | 416,356 |
Stock Information
| Shares Outstanding | 30.88M |
| Total Debt | $100.29M |
| Cash Equivalents | $17.18M |
| Revenue | $680K |
| Net Income | $-75.33M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $37.05M |
| EPS (TTM) | $-4.77 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $120.16M |
| Sales | $680K |
| Income | $-75.33M |
| Book/sh | $-3.90 |
| Cash/sh | $0.56 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 0.32 |
| Current Ratio | 0.62 |
Returns & Margins
| ROA | -86.77% |
| Gross Margin | 36.32% |
| Operating Margin | -4962.62% |
Ownership
| Insider Ownership | 3.65% |
| Institutional Ownership | 18.72% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.78 |
| P/S | 54.49 |
| P/B | -0.31 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $1.17 |
| SMA50 | $1.15 |
| SMA200 | $1.79 |
| RSI | 53.49 |
| ATR | 0.0764 |
| Shares Float | 26.36M |
| Short Float | 11.63% |
| Short Ratio | 4.80 |
| Volatility | 0.32 |
| Rel Volume | 0.58 |
Performance History
| Week | +8.11% |
| Month | +11.11% |
| Quarter | -25.00% |
| 6 Months | -36.17% |
| YTD | -29.41% |
| Year | -26.83% |
| 3 Years | -99.63% |
| 5 Years | -99.80% |
| 10 Years | -99.32% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.20 | 416,356 |
| 2026-06-17 | $1.19 | 603,500 |
| 2026-06-16 | $1.20 | 921,200 |
| 2026-06-15 | $1.16 | 823,600 |
| 2026-06-12 | $1.14 | 488,700 |
| 2026-06-11 | $1.11 | 749,200 |
| 2026-06-10 | $1.09 | 501,800 |
| 2026-06-09 | $1.07 | 619,900 |
| 2026-06-08 | $1.11 | 575,000 |
| 2026-06-05 | $1.11 | 992,800 |
| 2026-06-04 | $1.23 | 791,700 |
| 2026-06-03 | $1.16 | 330,500 |
| 2026-06-02 | $1.19 | 531,900 |
| 2026-06-01 | $1.19 | 547,000 |
| 2026-05-29 | $1.17 | 1,050,300 |
| 2026-05-28 | $1.26 | 1,445,000 |
| 2026-05-27 | $1.31 | 1,736,800 |
| 2026-05-26 | $1.22 | 518,700 |
| 2026-05-22 | $1.13 | 348,900 |
| 2026-05-21 | $1.14 | 388,200 |
| 2026-05-20 | $1.09 | 500,200 |
| 2026-05-19 | $1.08 | 502,400 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
đ° Latest News
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
Zacks âĸ 2026-06-02T16:00:08Z
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T12:15:01Z
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-05-14T12:45:03Z
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T23:05:21Z
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
Zacks âĸ 2026-05-04T14:00:10Z
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns
Insider Monkey âĸ 2026-04-17T13:36:32Z
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks
Simply Wall St. âĸ 2026-04-13T16:11:37Z
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks
Simply Wall St. âĸ 2026-03-29T16:04:35Z
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs
Simply Wall St. âĸ 2026-03-12T18:13:23Z
1 Top Penny Stock to Watch Now
Barchart âĸ 2026-01-17T17:00:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $164,000 | $2,143,000 | $1,260,000 | $20,000 |
| Cost Of Revenue | $164,000 | $2,143,000 | $1,260,000 | $20,000 |
| Total Revenue | $642,000 | $2,266,000 | $1,380,000 | $375,000 |
| Operating Revenue | $642,000 | $2,266,000 | $1,380,000 | $375,000 |
| Expenses | ||||
| Interest Expense | $16,984,000 | $15,129,000 | $13,314,000 | $8,213,000 |
| Total Expenses | $50,909,000 | $67,070,000 | $168,999,000 | $160,020,000 |
| Other Income Expense | $-3,712,000 | $17,732,000 | $-3,769,000 | $-427,000 |
| Other Non Operating Income Expenses | $-3,518,000 | $20,173,000 | $394,000 | $-427,000 |
| Net Non Operating Interest Income Expense | $-15,918,000 | $-12,527,000 | $-7,665,000 | $-5,685,000 |
| Interest Expense Non Operating | $16,984,000 | $15,129,000 | $13,314,000 | $8,213,000 |
| Operating Expense | $50,745,000 | $64,927,000 | $167,739,000 | $160,000,000 |
| Selling And Marketing Expense | $407,000 | $1,389,000 | $12,485,000 | $13,006,000 |
| General And Administrative Expense | $20,087,000 | $33,103,000 | $70,928,000 | $55,755,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Net Interest Income | $-15,918,000 | $-12,527,000 | $-7,665,000 | $-5,685,000 |
| Interest Income | $1,066,000 | $2,602,000 | $5,649,000 | $2,528,000 |
| Normalized Income | $-69,703,000 | $-57,158,000 | $-174,890,000 | $-165,757,000 |
| Net Income From Continuing And Discontinued Operation | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Total Operating Income As Reported | $-50,461,000 | $-67,245,000 | $-171,782,000 | $-159,645,000 |
| Net Income Common Stockholders | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Net Income | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Net Income Including Noncontrolling Interests | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Net Income Continuous Operations | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Pretax Income | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Special Income Charges | $-194,000 | $-2,441,000 | $-4,163,000 | $0 |
| Interest Income Non Operating | $1,066,000 | $2,602,000 | $5,649,000 | $2,528,000 |
| Operating Income | $-50,267,000 | $-64,804,000 | $-167,619,000 | $-159,645,000 |
| Gross Profit | $478,000 | $123,000 | $120,000 | $355,000 |
| Per Share | ||||
| Diluted EPS | $-5.73 | $-23.51 | $-98.40 | $-94.72 |
| Basic EPS | $-5.73 | $-23.51 | $-98.40 | $-94.72 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-52,419,000 | $-41,720,000 | $-161,258,000 | $-157,217,000 |
| Total Unusual Items | $-194,000 | $-2,441,000 | $-4,163,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-194,000 | $-2,441,000 | $-4,163,000 | $0 |
| Reconciled Depreciation | $300,000 | $309,000 | $318,000 | $327,000 |
| EBITDA (Bullshit earnings) | $-52,613,000 | $-44,161,000 | $-165,421,000 | $-157,217,000 |
| EBIT | $-52,913,000 | $-44,470,000 | $-165,739,000 | $-157,544,000 |
| Diluted Average Shares | $12,208,000 | $2,535,000 | $1,820,562 | $1,750,937 |
| Basic Average Shares | $12,208,000 | $2,535,000 | $1,820,562 | $1,750,937 |
| Diluted NI Availto Com Stockholders | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Restructuring And Mergern Acquisition | $194,000 | $2,441,000 | $4,163,000 | $0 |
| Research And Development | $30,251,000 | $30,435,000 | $84,326,000 | $91,239,000 |
| Selling General And Administration | $20,494,000 | $34,492,000 | $83,413,000 | $68,761,000 |
| Other Gand A | $12,386,000 | $19,672,000 | $29,724,000 | $19,916,000 |
| Insurance And Claims | $1,444,000 | $1,671,000 | $1,743,000 | $2,370,000 |
| Salaries And Wages | $6,257,000 | $11,760,000 | $39,461,000 | $33,469,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-95,463,000 | $-93,101,000 | $-56,508,000 | $76,775,000 |
| Total Assets | $44,916,000 | $38,338,000 | $73,702,000 | $205,853,000 |
| Total Non Current Assets | $231,000 | $944,000 | $1,559,000 | $2,985,000 |
| Current Assets | $44,685,000 | $37,394,000 | $72,143,000 | $202,868,000 |
| Other Current Assets | $10,945,000 | $1,440,000 | $2,078,000 | $3,843,000 |
| Restricted Cash | $342,000 | $0 | - | - |
| Prepaid Assets | $4,028,000 | $5,290,000 | $2,782,000 | $3,067,000 |
| Inventory | $722,000 | $679,000 | $1,991,000 | $1,985,000 |
| Receivables | $233,000 | $131,000 | $71,000 | $248,000 |
| Accounts Receivable | $233,000 | $131,000 | $71,000 | $248,000 |
| Cash Cash Equivalents And Short Term Investments | $28,415,000 | $29,854,000 | $65,221,000 | $193,725,000 |
| Cash And Cash Equivalents | $28,415,000 | $29,854,000 | $65,221,000 | $193,725,000 |
| Other Non Current Assets | - | $87,000 | $87,000 | $925,000 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Net Debt | $81,179,000 | $72,654,000 | $35,377,000 | - |
| Total Debt | $109,659,000 | $102,573,000 | $101,038,000 | $93,837,000 |
| Long Term Debt And Capital Lease Obligation | $84,663,000 | $102,573,000 | $101,038,000 | $93,837,000 |
| Long Term Debt | $84,663,000 | $102,508,000 | $100,598,000 | $93,051,000 |
| Current Debt And Capital Lease Obligation | $24,996,000 | $374,000 | $346,000 | $319,000 |
| Current Debt | $24,931,000 | - | - | - |
| Other Current Borrowings | $24,931,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $140,379,000 | $131,439,000 | $130,210,000 | $129,078,000 |
| Total Non Current Liabilities Net Minority Interest | $86,453,000 | $109,206,000 | $102,943,000 | $96,180,000 |
| Derivative Product Liabilities | $1,790,000 | $6,633,000 | $1,905,000 | $2,343,000 |
| Current Liabilities | $53,926,000 | $22,233,000 | $27,267,000 | $32,898,000 |
| Other Current Liabilities | $9,750,000 | $374,000 | $346,000 | $404,000 |
| Payables And Accrued Expenses | $19,146,000 | $21,824,000 | $26,758,000 | $26,124,000 |
| Payables | $14,871,000 | $16,188,000 | $13,877,000 | $10,732,000 |
| Total Tax Payable | $32,000 | $91,000 | $116,000 | $82,000 |
| Accounts Payable | $14,701,000 | $15,990,000 | $13,654,000 | $10,228,000 |
| Interest Payable | - | $0 | $736,000 | $3,175,000 |
| Equity | ||||
| Common Stock Equity | $-95,463,000 | $-93,101,000 | $-56,508,000 | $76,775,000 |
| Total Equity Gross Minority Interest | $-95,463,000 | $-93,101,000 | $-56,508,000 | $76,775,000 |
| Stockholders Equity | $-95,463,000 | $-93,101,000 | $-56,508,000 | $76,775,000 |
| Retained Earnings | $-720,094,000 | $-650,197,000 | $-590,598,000 | $-411,545,000 |
| Other | ||||
| Ordinary Shares Number | $22,328,000 | $3,102,423 | $1,870,624 | $1,759,187 |
| Share Issued | $22,328,000 | $3,102,423 | $1,870,624 | $1,759,187 |
| Tangible Book Value | $-95,463,000 | $-93,101,000 | $-56,508,000 | $76,775,000 |
| Invested Capital | $14,131,000 | $9,407,000 | $44,090,000 | $169,826,000 |
| Working Capital | $-9,241,000 | $15,161,000 | $44,876,000 | $169,970,000 |
| Capital Lease Obligations | $65,000 | $65,000 | $440,000 | $786,000 |
| Total Capitalization | $-10,800,000 | $9,407,000 | $44,090,000 | $169,826,000 |
| Additional Paid In Capital | $624,555,000 | $557,047,000 | $534,060,000 | $488,292,000 |
| Capital Stock | $76,000 | $49,000 | $30,000 | $28,000 |
| Common Stock | $76,000 | $49,000 | $30,000 | $28,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $65,000 | $440,000 | $786,000 |
| Current Capital Lease Obligation | $65,000 | $374,000 | $346,000 | $319,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $34,000 | $35,000 | $163,000 | $6,370,000 |
| Current Accrued Expenses | $4,275,000 | $5,636,000 | $12,881,000 | $15,392,000 |
| Dueto Related Parties Current | $138,000 | $107,000 | $107,000 | $422,000 |
| Net PPE | $231,000 | $857,000 | $1,472,000 | $2,060,000 |
| Accumulated Depreciation | $-1,802,000 | $-1,502,000 | $-1,193,000 | $-885,000 |
| Gross PPE | $2,033,000 | $2,359,000 | $2,665,000 | $2,945,000 |
| Leases | $1,200,000 | $1,200,000 | $1,200,000 | $1,181,000 |
| Machinery Furniture Equipment | $777,000 | $777,000 | $777,000 | $788,000 |
| Buildings And Improvements | $56,000 | $382,000 | $688,000 | $976,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $37,000 | $173,000 | $405,000 | $595,000 |
| Work In Process | $368,000 | $0 | $651,000 | $708,000 |
| Raw Materials | $317,000 | $506,000 | $935,000 | $682,000 |
| Construction In Progress | - | - | - | $0 |
| Other Properties | - | - | - | $976,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-57,615,000 | $-72,027,000 | $-155,026,000 | $-135,480,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-57,615,000 | $-72,027,000 | $-155,006,000 | $-135,341,000 |
| Cash Flow From Continuing Operating Activities | $-57,615,000 | $-72,027,000 | $-155,006,000 | $-135,341,000 |
| Operating Gains Losses | $3,505,000 | $-20,180,000 | $-436,000 | $411,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $-20,000 | $-139,000 |
| Cash Flow From Continuing Investing Activities | $0 | $0 | $-20,000 | $-139,000 |
| Capital Expenditure | - | - | $-20,000 | $-139,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $58,142,000 | $39,688,000 | $27,032,000 | $0 |
| Financing Cash Flow | $56,518,000 | $36,660,000 | $26,522,000 | $96,237,000 |
| Cash Flow From Continuing Financing Activities | $56,518,000 | $36,660,000 | $26,522,000 | $96,237,000 |
| Net Other Financing Charges | $-1,624,000 | $-528,000 | $-1,018,000 | $-2,646,000 |
| Net Common Stock Issuance | $58,142,000 | $39,688,000 | $27,032,000 | $0 |
| Common Stock Issuance | $58,142,000 | $39,688,000 | $27,032,000 | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-2,500,000 | $0 | - |
| Interest Paid Supplemental Data | $9,690,000 | $7,968,000 | $7,551,000 | $2,697,000 |
| End Cash Position | $28,757,000 | $29,854,000 | $65,221,000 | $193,725,000 |
| Beginning Cash Position | $29,854,000 | $65,221,000 | $193,725,000 | $232,968,000 |
| Changes In Cash | $-1,097,000 | $-35,367,000 | $-128,504,000 | $-39,243,000 |
| Net Issuance Payments Of Debt | $0 | $-2,500,000 | $0 | $98,600,000 |
| Net Long Term Debt Issuance | $0 | $-2,500,000 | $0 | $98,600,000 |
| Long Term Debt Payments | $0 | $-2,500,000 | $0 | - |
| Net PPE Purchase And Sale | $0 | $0 | $-20,000 | $-139,000 |
| Purchase Of PPE | $0 | $0 | $-20,000 | $-139,000 |
| Change In Working Capital | $-1,702,000 | $-6,029,000 | $2,018,000 | $10,403,000 |
| Change In Other Current Liabilities | $-374,000 | $-346,000 | $-319,000 | $-293,000 |
| Change In Payables And Accrued Expense | $6,973,000 | $-5,063,000 | $-722,000 | $16,834,000 |
| Change In Accrued Expense | $0 | $-736,000 | $2,497,000 | $3,804,000 |
| Change In Interest Payable | $0 | $-736,000 | $2,497,000 | $3,804,000 |
| Change In Payable | $6,973,000 | $-4,327,000 | $-3,219,000 | $13,030,000 |
| Change In Account Payable | $6,973,000 | $-4,327,000 | $-3,219,000 | $13,030,000 |
| Change In Prepaid Assets | $-8,156,000 | $-1,872,000 | $2,888,000 | $-3,905,000 |
| Change In Inventory | $-43,000 | $1,312,000 | $-6,000 | $-1,985,000 |
| Change In Receivables | $-102,000 | $-60,000 | $177,000 | $-248,000 |
| Changes In Account Receivables | $-102,000 | $-60,000 | $177,000 | $-248,000 |
| Other Non Cash Items | $7,412,000 | $7,316,000 | $3,533,000 | $1,938,000 |
| Stock Based Compensation | $2,767,000 | $6,156,000 | $18,614,000 | $17,337,000 |
| Depreciation Amortization Depletion | $300,000 | $309,000 | $318,000 | $327,000 |
| Depreciation And Amortization | $300,000 | $309,000 | $318,000 | $327,000 |
| Depreciation | $300,000 | $309,000 | $318,000 | $327,000 |
| Gain Loss On Investment Securities | $3,505,000 | $-20,180,000 | $-438,000 | $389,000 |
| Net Income From Continuing Operations | $-69,897,000 | $-59,599,000 | $-179,053,000 | $-165,757,000 |
| Proceeds From Stock Option Exercised | - | $0 | $508,000 | $283,000 |
| Gain Loss On Sale Of PPE | - | $0 | $2,000 | $22,000 |
| Issuance Of Debt | - | - | $0 | $98,600,000 |
| Long Term Debt Issuance | - | - | $0 | $98,600,000 |
| Change In Other Current Assets | - | - | - | $271,000 |
| Common Stock Payments | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-17